Heparin-induced thrombocytopenia (HIT) is an under-recognized, limb-and life-threatening complication of pharmacologic heparin administration. Antibody formation against heparin complexed to platelet factor 4 (PF4) is central to the pathogenesis of HIT. Heparin:PF4 antibodies promote platelet activation and aggregation as well as excess thrombin generation which may lead to clinical thrombosis. HIT should be suspected in patients who develop thrombocytopenia with or without associated arterial or venous thrombosis while on heparin. HIT is a clinical diagnosis. Specialized HIT assays should be interpreted with care. The cornerstone of HIT management is the discontinuation of all forms of heparin exposure and the institution of anticoagulation with an alternative agent. The direct thrombin inhibitors lepirudin and argatroban are currently available and approved for use in patients with HIT.
Introduction
Heparin-induced thrombocytopenia (HIT), also known as the 'white clot syndrome', is a relatively common, and often under-recognized, potentially devastating immunemediated complication of pharmacologic heparin administration. [1] [2] [3] HIT with associated paradoxical thrombosis (HITT) constitutes the major life-and limb-threatening complication of HIT. 1 The facts that thrombocytopenia is most commonly associated with a bleeding tendency and that heparin is most commonly employed to prevent and treat pathologic thrombosis add to the mystery and underappreciation of HIT(T). The prompt consideration of HIT(T) in patients who develop thrombocytopenia during heparin therapy, with or without new or propagating venous and arterial thromboses, is the cornerstone to appropriate HIT(T) diagnosis. Immediate discontinuation of all forms and routes of heparin exposure constitutes the essential component of HIT(T) treatment. arin:PF4 complexes, but IgM and IgA class antibodies targeted against heparin:PF4 have also been described. 5, 6 The immune complexes comprised of heparin, PF4 and antiheparin:PF4 antibodies (HIT-IgG) can interact with platelet Fc␥II receptors leading to potent platelet activation, platelet aggregation, and a marked increase in thrombin generation. 5, 7 HIT-IgG can also bind to platelet surface bound heparin:PF4 complexes leading to activation of the same or adjacent platelets. PF4 released from these activated platelets can form additional complexes with heparin and facilitate the generation of additional HIT-IgG and platelet activation. 8 In addition to initiating platelet activation, HIT sera, in the presence of heparin, generates the formation of procoagulant platelet microparticles that appear to eminate from pseudopodia of activated platelets. The physiologic role of the microparticles remains undetermined. 9, 10 HIT-IgG has also been demonstrated to activate the endothelium in vitro, by interacting with heparan:PF4 complexes formed on the endothelial cell surface. 5 Heparan is an endogenous glycosaminoglycan which likely functions as a natural anticoagulant on normal vascular endothelium. Theoretically, the endothelial cell activation induced by HIT-IgG may lead to increased tissue factor synthesis, which may further contribute to excess thrombin generation, thrombus formation, and platelet activation. Endothelial cell hyperplasia as a result of immune-mediated injury may also play a role in the small vessel thrombosis and occlusive disease observed in HIT. 11 HITT most likely constitutes a more severe and protracted form of HIT with evidence of macrovascular thrombosis or thrombus-induced end-organ dysfunction.
Natural history
HIT usually develops between 5 and 14 days after the commencement of heparin therapy and produces a variable but often profound degree of thrombocytopenia. 12, 13 A platelet count fall that begins prior to day 5 of heparin is not likely to represent HIT except in patients with a recent (within 3 months) heparin exposure. 1 These patients may experience an abrupt onset of thrombocytopenia upon re-exposure to heparin as a result of acute platelet activation due to preformed, circulating HIT-associated antibodies.
Though the exact incidence of HIT has not been wellestablished, HIT has been noted to develop in up to 3-5% of patients exposed to unfractionated porcine intestinederived heparin (UFH). Early reports that cited an incidence as high as 30% lacked a clear definition of thrombocytopenia and failed to differentiate HIT from non-immunemediated heparin-associated thrombocytopenia. 14 In all, 36-50% of patients with HIT have been noted to develop life-or limb-threatening thromboses as a result of HITT. 15 The thrombotic tendency associated with HIT can last for at least 30 days and HITT can develop well after the discontinuation of heparin and platelet count recovery. The fact that the thrombocytopenia seen in HIT usually resolves within 3-7 days of heparin withdrawal is a useful aid to making the diagnosis of HIT.
Patients exposed to bovine lung-derived UFH have been reported to have a greater likelihood of developing HIT than those exposed to porcine intestine-derived UFH. 16 HIT(T) appears to occur infrequently, though, as a result of primary low molecular weight heparin (LMWH) therapy in heparin naive individuals. 1 Warkentin et al 1 evaluated the incidence of HIT(T) in 665 patients randomized to receive subcutaneous UFH or LMWH for venous thromboprophylaxis following elective hip surgery. HIT was diagnosed in 2.7% (9/332) of patients given UFH versus 0% (0/333) of those given LMWH. HITT developed in 88.9% (8/9) of the patients who developed HIT compared with a thrombosis rate of 17.8% (117/656) in patients without HIT. This study substantiated previous reports of discordance between HIT-IgG formation and the development of clinical HIT. HIT-IgG was detected in 7.8% and 2.2% of patients treated with UFH and LMWH respectively. These rates of 'seroconversion' are considerably higher than the documented HIT rates of 2.7% and 0% respectively. 1 Such seroconversion has been documented in up to 17% of heparin-treated patients and 8% of LMWH-treated patients. 17 The difference in seroconversion rate may stem from the fact that LMWHs appear to less readily complex with PF4 than UFH and thus generate less of an immune response.
The development of HIT-IgG and clinical HIT appears to vary between patient group. Following cardiopulmonary bypass (CPB) and exposure to UFH, 25-50% of patients have detectable HIT-IgG but only a minority develop HIT(T). [18] [19] [20] The presence or absence of HIT-IgG prior to CPB does not seem to predict for any adverse clinical postoperative outcome. Lindhoff-Last et al identified HIT-IgG in 34% (17/50) of patients anticoagulated with heparin following vascular surgery, with 24% (4/17) developing recurrent arterial thromboses. 21 In pediatric populations, descriptions of HIT-IgG formation and clinical HIT are limited to a few case reports. 22, 23 Immune-mediated HIT (formally known as type II HIT) must be differentiated from the far more common and benign non-immune heparin-associated thrombocytopenia (formally known as type I HIT). Non-immune heparinassociated thrombocytopenia is most commonly observed following large doses of heparin, has an incidence of up to 10%, and is not detected by the usual HIT diagnostic assays. Non-immune heparin-associated thrombocytopenia is associated with mild thrombocytopenia (rarely less than 100 000 platelets/l), which develops within the initial 1-2 days of heparin exposure. The platelet count fall may be related to a direct activating effect on platelets by heparin. 3 The platelet count typically normalizes despite continued heparin exposure. Unlike HIT, no significant adverse clinical events, such as thrombosis, are associated with this entity and heparin administration may be continued. 2, 24 
Clinical presentation
Thrombosis is the major complication of HIT. Venous thrombosis is more common than arterial thrombosis in HIT patients, especially in those who receive heparin for postoperative deep venous thrombosis prevention. 13, 25 Extremity deep vein thrombosis is the most frequently encountered venous thrombotic complication in HIT patients followed in frequency by pulmonary embolism and cerebral sinus thrombosis. 2 Most HIT-associated arterial thromboses involve the extremities, but stroke, myocardial infarction and renal artery thrombosis related to heparin infusions have been described. 26 HITT following coronary artery bypass grafting may present as bypass graft occlusion, left atrial thrombus formation, valvular thrombosis, or pulmonary embolism. 26 Acute graft occlusion secondary to HIT has been described in vascular surgery patients even following platelet count normalization. It is reasonable to assume that patients with pre-existing vascular lesions, intravascular catheters, sepsis, and postoperative venous stasis are particularly susceptible to the thrombotic complications of HIT.
Other clinical presentations of HIT include heparininduced skin lesions, heparin 'resistance', and adrenal vein thrombosis leading to hemorrhagic infarction. 27, 28 Heparininduced skin lesions have been observed in approximately 10-20% of patients who generate HIT-IgG in response to subcutaneous UFH injections. The skin lesions develop at heparin injection sites and can range from painful, red plaques to overt skin necrosis reminiscent of warfarin-induced skin necrosis. Thrombocytopenia may not develop in the majority of patients with heparin-induced skin lesions, but those who develop skin lesions and thrombocytopenia appear to be at extremely high risk for arterial thrombosis. The thrombocytopenia that develops in HIT is not normally associated with hemorrhagic events and platelet transfusion may exacerbate the HIT-induced prothrombotic tendency. 3
Diagnosis
The differential diagnosis of acute thrombocytopenia in the medically and surgically ill can be extensive and complex. Thrombocytopenia in these settings can result from hemodilution, bone marrow failure, bacteremia, disseminated intravascular coagulation, and non-heparin medications. HIT must always be considered strongly because a failure to promptly discontinue all heparin and initiate an effective alternative antithrombotic agent can result in significant morbidity and mortality. HIT may not be the most common cause of acute thrombocytopenia but it certainly may be the most limb-and life-threatening.
HIT and HITT are primarily clinical diagnoses. Table 1 lists clinical features that may suggest a diagnosis of HIT. In general, HIT(T) should be strongly suspected in any patient who develops thrombocytopenia while receiving heparin in any dose or route of administration. While HIT(T) is usually associated with a platelet count below the lower limits of normal, 150 000/l in most laboratories, the degree of thrombocytopenia is quite variable and may be profound. 1 The diagnosis should be strongly considered in any patient in whom the platelet count falls below 50% of the baseline value (even if still within the normal range) after the fifth day of heparin treatment. A 30% fall in baseline platelet count combined with any form of thrombosis in a patient receiving heparin should be considered to be HITT until proven otherwise. Thrombotic events occurring or progressing during therapeutic intensity heparin therapy, even if the platelet count is normal, may constitute a HITT variant. 22, 30, 31 The identification of any platelet-rich 'white clot' during surgical thrombectomy or extracorporeal blood circulation alert health care personnel to the possible existence of HITT.
The currently available in vitro diagnostic assays for HIT are either functional assays or immunoassays. Functional assays detect normal platelet aggregation or platelet activation following exposure to suspected HIT serum and heparin. Functional assays include the platelet aggregation test (PAT), the heparin-induced platelet aggregation (HIPA) test, heparin-induced platelet release of ATP detected by lumi-aggregometry, the 14 C-serotonin-release assay (SRA), heparin-induced platelet microparticle formation detected by flow cytometry, and enzyme immunoassay detection of platelet serotonin release. Immunoassays detect the presence of heparin-PF4 antibodies using enzyme-linked immunosorbent assay (ELISA) methodology.
The most commonly used assays are the HIPA, 14 C-SRA, and the heparin: PF4 antibody ELISA. The HIPA is performed using normal donor washed platelets, the serum from a suspected HIT patient, and heparin in escalating concentrations. 32 HIPA may be performed using UFH, LMWH or danaparoid. Ideally, the laboratory should use the same drug during in vitro testing as has been administered to the patient in question. Normal donor platelet aggregation in the presence of patient serum and a low concentration of a particular drug constitutes a positive HIPA 33 These results must be interpreted with caution; other studies have reported less favorable results.
Traditionally, the 14 C-SRA has been considered the 'gold standard' for HIT diagnostic confirmation. However, most studies evaluating the diagnostic utility of the available functional assays and immunoassays, including studies of 14 C-SRA, used a clinical diagnosis of HIT as the true 'gold standard'. Therefore, we feel that HIT diagnostic assays should be reserved for HIT confirmation and possibly for anticoagulant cross-reactivity testing. In some instances, a HIT test may be used to confirm the absence of circulating functional HIT-IgG prior to repeat heparin exposures in patients with a questionable past diagnosis of HIT or if alternate antithrombotic agent use is deemed undesirable. It is the belief of the authors that a stereotypical clinical presentation suggestive of HIT should be treated as HIT even in the presence of normal HIPA, 14 C-SRA, or ELISA testing. Because of the inherent delay in receiving the results of HIT diagnostic assays and limited availability of such testing at many facilities, HIT management should begin at the earliest clinical recognition of the syndrome.
Treatment
Elimination of all heparin exposure is the most essential element in the treatment of HIT(T). This includes heparin intravenous catheter flushes, prophylactic subcutaneous heparin or LMWH, and heparin-coated indwelling catheters. Despite heparin discontinuation and platelet count recovery, though, patients with isolated, serologically-confirmed HIT have an approximately 50% risk of developing a confirmed thrombotic event during the 30-day period following heparin stoppage. 15 The persistent prothrombotic tendency associated with HIT, the presence of thrombus in HITT and a patient's original indication for heparin therapy all warrant use of an alternative anticoagulant agent following heparin cessation. Early cessation of heparin alone and the cessation of heparin combined with the initiation of warfarin therapy alone constitute inadequate HIT treatment. 34 Newer anticoagulants (Table 2) , which have been used with varying degrees of success for the management of patients with HIT(T), include lepirudin (Refludan  ), argatroban (Argatroban), and danaparoid sodium (Orgaran  ).
Lepirudin
Lepirudin is a recombinant hirudin analog that received US Food and Drug Administration (FDA) approval in 1998 for anticoagulant treatment in patients with HIT in the setting of thromboembolic disease in order to prevent further thrombosis. 36 Lepirudin differs from native hirudin, found in the saliva of the medicinal leech, in that it lacks sulfation on the tyrosine at position 63 and has a leucine at position 1 rather than isoleucine. 37 Lepirudin is a potent direct antithrombin that lacks any structural homology with heparin, does not cross-react with heparin, has a short halflife, is able to inactivate clot-bound thrombin, and can be monitored using the ubiquitous activated partial thromboplastin time (aPTT) assay or less readily available ecarin clotting time. 38 Published data on the use of lepirudin in patients with HIT(T) are limited. One prospective, multicenter, historically controlled study described lepirudin use in 82 patients with laboratory-confirmed HIT. 39 Fifty-one HIT patients with thrombosis received 0.4 mg/kg as a bolus followed by a continuous infusion of 0.15 mg/kg per h; five HIT patients with thrombosis receiving thrombolysis received a 0.2 mg/kg bolus followed by a 0.1 mg/kg per h infusion; 18 patients without thrombosis received a prophylactic infusion of 0.1 mg/kg per h; and eight patients undergoing CBP received a 0.25 mg/kg bolus and 5 mg boluses as needed. Platelet counts increased rapidly in 88.7% of lepirudin-treated patients with acute HIT. The incidence of the combined endpoint of death, amputation, and new thromboembolic events was reduced by greater than 50% (p = 0.014) in the group that received lepirudin compared with 120 historical controls. Bleeding events and transfusion requirements were no greater in the lepirudintreated patients.
Current lepirudin dosing recommendations for acute HIT management are 0.4 mg/kg as a bolus followed by 0.15 mg/kg per h (up to 110 kg). The target aPTT is 1.5-2.5 times the median value for the normal range. Monitoring during CPB requires performance of the less readily available ecarin clotting time with a target plasma lepirudin con-Vascular Medicine 2001; 6: 113-119 centration of 2.0 g/ml. 40 The activated clotting time (ACT) and point-of-care aPTT assays do not appear to be suitable for lepirudin therapeutic monitoring. 41 The major challenges of lepirudin treatment are the lack of an antidote, the extreme care needed when treating patients with even mild renal insufficiency, and immunogenicity. The lack of an antidote is also a challenge of treatment with argatroban and danaparoid. In the event of lepirudin overdose or lepirudin-induced bleeding, infusions of prothrombin complex concentrates or recombinant factor VIIa may help promote hemostasis. 36 High flux capillary hemodialysis membranes may facilitate the hemofiltration of lepirudin in some cases. 42 Partial exchange transfusions, plasmapheresis, and immobilized thrombin affinity columns have also been tried to neutralize the effects of lepirudin. 36 Marked bolus and infusion rate reductions are necessary in patients with a creatinine clearance of less than 60 ml/min (serum creatinine Ͼ1.6 mg/dl). Lepirudin is to be avoided completely or administered with extreme care in the settings of hemodialysis, acute renal failure, and in patients undergoing continuous veno-venous hemodialysis even in the setting of a normal serum creatinine. Careful monitoring of both the aPTT and serum creatinine are indicated during lepirudin therapy. 43 Approximately 40% of HIT patients treated with lepirudin develop anti-hirudin antibodies of the IgG class. 44 The antibodies seem to be capable of decreasing renal elimination of the drug rather than exerting any in vivo neutralizing effect. This paradoxical enhancement of the anticoagulant effect of lepirudin often warrants a significant infusion rate reduction.
Argatroban
Argatroban is a synthetic, small molecule, l-arginine derivative that received FDA approval in June 2000 for prophylaxis against and treatment of thrombosis in patients with HIT. Argatroban is a rapid and reversible direct thrombin inhibitor, in contrast to lepirudin which is an irreversible thrombin inhibitor. Argatroban is capable of inhibiting both free and fibrin-associated thrombin. Argatroban exerts its antithrombotic effects by inhibiting thrombin-mediated reactions including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of the natural anticoagulant protein C; and platelet activation. 45 Like lepirudin, argatroban does not cross-react with heparin. Argatroban is hepatically metabolized with biliary excretion and has a half-life of only 40 min. Renal excretion has also been documented; however, renal impairment has been shown to have little adverse effect on drug clearance and half-life. Unlike lepirudin, argatroban does not require dose adjustment in the setting of renal insufficiency. Dose reduction is required in patients with significant hepatic disease. 45 Published efficacy data for argatroban are limited. Lewis et al reported (in abstract form) findings from a large, prospective, historically controlled trial. 46 This study treated 160 patients with HIT alone and 144 patients with HIT and thrombosis with argatroban dosed to maintain an aPTT 1.5-3.0 times the baseline value. In patients with HIT alone, the combined incidence of death, amputation, and new thromboembolic events was significantly lower in argatroban recipients compared with controls (26% vs 39%; p = 0.014). In patients with HITT at baseline, the incidence of this combined endpoint was non-significantly lower in arga-troban recipients compared with controls (44% vs 57%; p = 0.131). Argatroban recipients also showed significant improvements in platelet count relative to the historical controls. No difference in bleeding events between the argatroban and control groups was noted.
Argatroban is dosed based on patient weight. The recommended starting intravenous infusion rate is 2 g/kg per min with a target aPTT of 1.5-3 times the baseline value. Therapy may also be monitored by whole blood ACT and the ecarin clotting time. Like lepirudin, argatroban prolongs the prothrombin time (PT) as well as the aPTT. This PT prolongation makes an accurate international normalized ratio (INR) determination during conversion to oral warfarin a challenge. Holding the infusion of either direct thrombin inhibitor for several hours before INR determination is prudent. A recent abstract presentation showed that argatroban provides adequate anticoagulation with minimal bleeding risk while enabling procedural success in HIT patients undergoing percutaneous coronary intervention. 47 Patients were given argatroban 350 g/kg as a bolus followed by 25 g/kg per min titrated to achieve an ACT of 300-450 s. This dosing regimen may provide satisfactory anticoagulation during CPB and allow intraoperative dose adjustments based on the readily available ACT.
Danaparoid
Danaparoid sodium is a glucosaminoglycan mixture derived from porcine intestinal mucosa composed of heparan sulfate (84%), dermatan sulfate (12%), and chondroitin sulfate (4%). Unlike lepirudin and argatroban, danaparoid is not a direct thrombin inhibitor. Danaparoid has an anti-factor Xa activity to anti-factor IIa activity ratio of greater than 22:1 (compared to a 1:1 ratio for heparin), which explains why it is minimally neutralized by protamine sulfate. 48 Unlike lepirudin and argatroban, danaparoid is not approved by the FDA for use in HIT(T) treatment, although it is used off-label for this indication. The largest collection of clinical experience with danaparoid is provided by Magnani, who published an overview of 230 patients treated for HIT. 49 Danaparoid was associated with a favorable outcome in 92.5% of patients. In the 15 patients considered to be treatment failures, two patients had bleeding events (one fatal), four developed recurrent thrombocytopenia, five had persistent thrombocytopenia, and four had thromboembolic events. Overall, five patients demonstrated danaparoid cross-reactivity with HIT-IgG (one developed a new thrombosis). Mortality reported as possibly or probably attributed to danaparoid treatment occurred in 3% of patients and included episodes of bleeding, thrombosis, and septic shock. In a recent series, Tardy-Poncet et al treated 42 patients with either therapeutic intensity (26 patients) or prophylactic intensity (16 patients) danaparoid. 50 No new thrombotic events were reported, two patients developed major bleeding, and two patients died as a result of HITT.
Danaparoid may cross-react with 10-50% of HIT sera, but in vivo cross-reactivity, although reported, has not been commonly observed. 51, 52 Danaparoid has a relatively long half-life of approximately 24 h that may make its use less desirable in patients at high risk of developing bleeding or those likely to need surgery. Significant experience exists with the administration of danaparoid by both intravenous and subcutaneous routes. Danaparoid anticoagulation is Vascular Medicine 2001; 6: 113-119 monitored using an anti-factor Xa activity chromogenic assay set up using danaparoid standards. The drug is commercially available for deep vein thromboprophylaxis following orthopedic surgery at a dose of 750 anti-Xa units twice daily by subcutaneous injection. A common dose for the treatment of active thrombosis in patients with normal renal function is 1500 units as an intravenous bolus followed by 1500 units subcutaneously twice daily. The target therapeutic anti-factor Xa activity is 0.5-0.8 U/ml. Danaparoid's potential for cross-reactivity and the longer half-life make it less desirable than lepirudin for the treatment of patients with HIT.
Low molecular weight heparins
Interest in LMWHs as a treatment for HIT stems from the observation that LMWH is less likely than unfractionated heparins to elicit HIT-IgG formation and less likely to cause clinical HIT and HITT. 1 Because of a high likelihood for in vitro and in vivo cross-reactivity (80-100%) of the HIT-IgG for LMWH, though, this class of anticoagulant may be harmful in patients who have circulating HIT-IgG. Case series clearly show that LMWH can precipitate catastrophic complications in patients with HIT. [53] [54] [55] [56] LMWH should not be used in patients with suspected or confirmed HIT.
Warfarin
Warfarin anticoagulation may be desired for long-term therapy, but should never be employed as the sole alternative anticoagulant in patients with HIT(T). Warfarin has the disadvantage of requiring at least 5 days to achieve full therapeutic effect and has been associated with venous limb gangrene when used alone. Warfarin treatment is the major factor contributing to limb amputation caused by the progression of otherwise unremarkable deep vein thromboses to phlegmasia cerulea dolens in patients with HIT. 57, 58 The combination of HIT-associated hypercoagulability and warfarin-induced protein C deficiency most likely produces a profound procoagulant state that causes venous limb gangrene. The existence of this syndrome justifies the absolute need for systemic anticoagulation with lepirudin, argatroban, or danaparoid during the initiation of warfarin anticoagulation in patients with HIT(T).
Adjuncts to alternative anticoagulant therapy in the management of HIT and HITT include antiplatelet agents (e.g. aspirin, ticlopidine, clopidogrel, and glycoprotein IIb/IIIa inhibitors), high-dose intravenous gammaglobulin and prostacyclin analogue (iloprost) infusion. 3, 59 The benefit of these agents is primarily anecdotal in nature. Interest in using parenteral and oral platelet glycoprotein IIb/IIIa inhibitors to reverse the harmful platelet aggregation found in HIT is mounting. In vitro, glycoprotein IIb/IIIa antagonists inhibit HIT-IgG-induced platelet aggregation, but in vivo data are limited. 60, 61 Walenga et al reported the successful use of a direct thrombin inhibitor combined with tirofiban or abciximab in three patients with HIT. 62 Surgical thromboembolectomy and pharmacological thrombolysis should be reserved for selected patients. 3 Thromboembolectomy may provide limited benefit in patients with limb artery occlusion because of the diffuse nature of the thrombotic process which extends into the small vasculature. The administration of thrombolytic agents to patients with HIT and thrombosis has the added benefit of promoting antic-oagulation secondary to fibrinogen depletion and fibrindegradation product accumulation. In addition to alternative pharmaceutical options for management, plasmapheresis has been used in a few selected instances. 63 One area of HIT management that deserves special attention involves patients with a history of HIT(T) who require CPB for open heart surgery. While experience with direct thrombin inhibitors and danaparoid during CPB is mounting, the issues of specialized intra-operative therapeutic monitoring and the lack of specific antidotes have been gaining attention. Because of familiarity with the drug, its monitoring, and reversal, some surgeons continue to prefer heparin during CPB. One strategy to reduce the likelihood of paradoxical thrombosis during CPB in patients with HIT is to limit the heparin exposure to as brief a period as possible and administer heparin only if HIT-IgG testing is negative prior to surgery. Because it has been shown that 89% of patients with HIT will test negative for HIT-IgG within 100 days of their last heparin exposure, delaying surgery for 3 months after a heparin exposure seems wise. 64 Pötzsch et al studied 10 patients with a history of HIT who underwent CPB with intra-operative heparin. None of the patients developed prolonged thrombocytopenia and none demonstrated an increase in HIT-IgG titers following surgery. 65
Prevention
Considering the complexity of HIT diagnosis and treatment, HIT prevention must be emphasized. Patients receiving heparin should have platelet count monitoring at baseline and at least every third day between day 5 and day 14 of heparin exposure. Early oral warfarin anticoagulation initiation in patients receiving heparin therapy for an acute thrombosis or atrial fibrillation should allow the duration of heparin exposure to be kept to a minimum and hopefully under 5 days. Appropriate medical record documentation and patient education should help avert heparin re-exposure in patients with a history of HIT(T). Re-exposure to heparin in patients with past HIT(T) should be delayed at least 3 months, be kept to a minimum duration to provide succinct anamnesis, and avoided whenever possible. LMWH may be preferable to unfractionated heparin for both the treatment and prevention of thromboembolic disease because of the greatly reduced likelihood of instigating HIT(T). Currently, the direct thrombin inhibitors lepirudin and argatroban, when used with caution, appear to be the best available drugs for the treatment of HIT(T).
